Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of the lower limbs

R. A. Mangiafico, L. S. Malatino, M. Santonocito, R. S. Spada

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Endothelin-1 (ET-1), a vasoconstrictor and mitogenic endothelium-derived peptide, has been considered as a marker for endothelial damage and potential contributor to the development of the atherogenic process. Methods. To evaluate the pattern of plasma ET-1 secretion in non-insulin-dependent diabetes mellitus (NIDDM) and nondiabetic patients with chronic arterial obstructive disease (CAOD) of the lower limbs, plasma levels of ET-1 were determined in 12 NIDDM patients (10 men and 2 women; mean age 63 ± 8 years) with CAOD of the lower limbs at Fontaine stage II and in 12 nondiabetic patients (11 men and 1 woman; mean age 62 ± 4 years) with comparable arteriopathy. Ten normal subjects comprised the control population. Results. The plasma levels of ET-1 in NIDDM patients with CAOD of the lower limbs were 5.7 ± 0.3 pmol/L, which represented a significant (p <0.001) difference from the values in nondiabetic patients with comparable arteriopathy (4.1 ± 0.6 pmol/L) and those in the control group (2.7 ± 0.7 pmol/L). Plasma levels of ET-1 showed a significant (p <0.0001) positive correlation with the levels of fasting insulin in NIDDM patients with CAOD of the lower limbs. Increased plasma ET-1 could reflect a major and/or more diffuse endothelial cell damage or dysfunction in NIDDM than in nondiabetic patients with comparable CAOD of the lower limbs. Augmented mitogenic ET-1 levels could also have a role both in diabetic and nondiabetic angiopathy. Conclusions. The positive correlation between ET-1 plasma levels and fasting insulin levels in NIDDM patients with CAOD of the lower limbs suggests that the increased ET-1 release could be related to the augmented insulin secretion in these patients. Insulin-related overproduction of ET-1 could promote the atherogenic process and enhance the vascular tone to a greater extent in NIDDM than in nondiabetic patients with CAOD of the lower limbs.

Original languageEnglish
Pages (from-to)97-102
Number of pages6
JournalInternational Angiology
Volume17
Issue number2
Publication statusPublished - Jun 1998

Fingerprint

Arterial Occlusive Diseases
Endothelin-1
Type 2 Diabetes Mellitus
Lower Extremity
Insulin
Fasting
Diabetic Angiopathies
Vasoconstrictor Agents
Endothelium
Blood Vessels
Endothelial Cells

Keywords

  • Arterial occlusive diseases
  • Chronic diseases
  • Diabetes mellitus, non insulin dependent
  • Endothelin-1

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of the lower limbs. / Mangiafico, R. A.; Malatino, L. S.; Santonocito, M.; Spada, R. S.

In: International Angiology, Vol. 17, No. 2, 06.1998, p. 97-102.

Research output: Contribution to journalArticle

@article{43b32a4f58cf498fb3ed24b85384233e,
title = "Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of the lower limbs",
abstract = "Endothelin-1 (ET-1), a vasoconstrictor and mitogenic endothelium-derived peptide, has been considered as a marker for endothelial damage and potential contributor to the development of the atherogenic process. Methods. To evaluate the pattern of plasma ET-1 secretion in non-insulin-dependent diabetes mellitus (NIDDM) and nondiabetic patients with chronic arterial obstructive disease (CAOD) of the lower limbs, plasma levels of ET-1 were determined in 12 NIDDM patients (10 men and 2 women; mean age 63 ± 8 years) with CAOD of the lower limbs at Fontaine stage II and in 12 nondiabetic patients (11 men and 1 woman; mean age 62 ± 4 years) with comparable arteriopathy. Ten normal subjects comprised the control population. Results. The plasma levels of ET-1 in NIDDM patients with CAOD of the lower limbs were 5.7 ± 0.3 pmol/L, which represented a significant (p <0.001) difference from the values in nondiabetic patients with comparable arteriopathy (4.1 ± 0.6 pmol/L) and those in the control group (2.7 ± 0.7 pmol/L). Plasma levels of ET-1 showed a significant (p <0.0001) positive correlation with the levels of fasting insulin in NIDDM patients with CAOD of the lower limbs. Increased plasma ET-1 could reflect a major and/or more diffuse endothelial cell damage or dysfunction in NIDDM than in nondiabetic patients with comparable CAOD of the lower limbs. Augmented mitogenic ET-1 levels could also have a role both in diabetic and nondiabetic angiopathy. Conclusions. The positive correlation between ET-1 plasma levels and fasting insulin levels in NIDDM patients with CAOD of the lower limbs suggests that the increased ET-1 release could be related to the augmented insulin secretion in these patients. Insulin-related overproduction of ET-1 could promote the atherogenic process and enhance the vascular tone to a greater extent in NIDDM than in nondiabetic patients with CAOD of the lower limbs.",
keywords = "Arterial occlusive diseases, Chronic diseases, Diabetes mellitus, non insulin dependent, Endothelin-1",
author = "Mangiafico, {R. A.} and Malatino, {L. S.} and M. Santonocito and Spada, {R. S.}",
year = "1998",
month = "6",
language = "English",
volume = "17",
pages = "97--102",
journal = "International Angiology",
issn = "0392-9590",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of the lower limbs

AU - Mangiafico, R. A.

AU - Malatino, L. S.

AU - Santonocito, M.

AU - Spada, R. S.

PY - 1998/6

Y1 - 1998/6

N2 - Endothelin-1 (ET-1), a vasoconstrictor and mitogenic endothelium-derived peptide, has been considered as a marker for endothelial damage and potential contributor to the development of the atherogenic process. Methods. To evaluate the pattern of plasma ET-1 secretion in non-insulin-dependent diabetes mellitus (NIDDM) and nondiabetic patients with chronic arterial obstructive disease (CAOD) of the lower limbs, plasma levels of ET-1 were determined in 12 NIDDM patients (10 men and 2 women; mean age 63 ± 8 years) with CAOD of the lower limbs at Fontaine stage II and in 12 nondiabetic patients (11 men and 1 woman; mean age 62 ± 4 years) with comparable arteriopathy. Ten normal subjects comprised the control population. Results. The plasma levels of ET-1 in NIDDM patients with CAOD of the lower limbs were 5.7 ± 0.3 pmol/L, which represented a significant (p <0.001) difference from the values in nondiabetic patients with comparable arteriopathy (4.1 ± 0.6 pmol/L) and those in the control group (2.7 ± 0.7 pmol/L). Plasma levels of ET-1 showed a significant (p <0.0001) positive correlation with the levels of fasting insulin in NIDDM patients with CAOD of the lower limbs. Increased plasma ET-1 could reflect a major and/or more diffuse endothelial cell damage or dysfunction in NIDDM than in nondiabetic patients with comparable CAOD of the lower limbs. Augmented mitogenic ET-1 levels could also have a role both in diabetic and nondiabetic angiopathy. Conclusions. The positive correlation between ET-1 plasma levels and fasting insulin levels in NIDDM patients with CAOD of the lower limbs suggests that the increased ET-1 release could be related to the augmented insulin secretion in these patients. Insulin-related overproduction of ET-1 could promote the atherogenic process and enhance the vascular tone to a greater extent in NIDDM than in nondiabetic patients with CAOD of the lower limbs.

AB - Endothelin-1 (ET-1), a vasoconstrictor and mitogenic endothelium-derived peptide, has been considered as a marker for endothelial damage and potential contributor to the development of the atherogenic process. Methods. To evaluate the pattern of plasma ET-1 secretion in non-insulin-dependent diabetes mellitus (NIDDM) and nondiabetic patients with chronic arterial obstructive disease (CAOD) of the lower limbs, plasma levels of ET-1 were determined in 12 NIDDM patients (10 men and 2 women; mean age 63 ± 8 years) with CAOD of the lower limbs at Fontaine stage II and in 12 nondiabetic patients (11 men and 1 woman; mean age 62 ± 4 years) with comparable arteriopathy. Ten normal subjects comprised the control population. Results. The plasma levels of ET-1 in NIDDM patients with CAOD of the lower limbs were 5.7 ± 0.3 pmol/L, which represented a significant (p <0.001) difference from the values in nondiabetic patients with comparable arteriopathy (4.1 ± 0.6 pmol/L) and those in the control group (2.7 ± 0.7 pmol/L). Plasma levels of ET-1 showed a significant (p <0.0001) positive correlation with the levels of fasting insulin in NIDDM patients with CAOD of the lower limbs. Increased plasma ET-1 could reflect a major and/or more diffuse endothelial cell damage or dysfunction in NIDDM than in nondiabetic patients with comparable CAOD of the lower limbs. Augmented mitogenic ET-1 levels could also have a role both in diabetic and nondiabetic angiopathy. Conclusions. The positive correlation between ET-1 plasma levels and fasting insulin levels in NIDDM patients with CAOD of the lower limbs suggests that the increased ET-1 release could be related to the augmented insulin secretion in these patients. Insulin-related overproduction of ET-1 could promote the atherogenic process and enhance the vascular tone to a greater extent in NIDDM than in nondiabetic patients with CAOD of the lower limbs.

KW - Arterial occlusive diseases

KW - Chronic diseases

KW - Diabetes mellitus, non insulin dependent

KW - Endothelin-1

UR - http://www.scopus.com/inward/record.url?scp=0031726856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031726856&partnerID=8YFLogxK

M3 - Article

C2 - 9754897

AN - SCOPUS:0031726856

VL - 17

SP - 97

EP - 102

JO - International Angiology

JF - International Angiology

SN - 0392-9590

IS - 2

ER -